Cristina Vazquez Guillamet

Medicine & Life Sciences

1. Septic Shock 100%
2. Infections 88%
3. Critical Illness 81%
4. Anti-Bacterial Agents 73%
5. Ventilator-Associated Pneumonia 71%
6. Sepsis 65%
7. Lung 59%
8. Methicillin-Resistant Staphylococcus aureus 59%
9. Transplant Recipients 57%
10. Mortality 54%
11. Intensive Care Units 45%
12. Artificial Respiration 38%
13. Gram-Negative Bacteria 35%
14. Acinetobacter 35%
15. Pneumonia 33%
16. Cohort Studies 31%
17. Microbial Drug Resistance 30%
18. Healthcare-Associated Pneumonia 29%
19. Hospital Rapid Response Team 29%
20. B7-H1 Antigen 28%
21. Antimicrobial Stewardship 28%
22. Bacteremia 28%
23. Cefepime 27%
24. Therapeutics 27%
25. Coronavirus 27%
26. Clinical Decision Rules 26%
27. Skilled Nursing Facilities 25%
28. Candidemia 25%
29. Epidemiology 25%
30. Soft Tissue Infections 25%
31. Meropenem 25%
32. Tazobactam Drug Combination Piperacillin 24%
33. Terminal Care 24%
34. Gram-Positive Bacteria 23%
35. Pseudomonas 23%
36. Critical Care 23%
37. Numbers Needed To Treat 23%
38. Hospital Mortality 22%
39. Odds Ratio 22%
40. Confidence Intervals 22%
41. Immunocompromised Host 22%
42. Multiple Drug Resistance 21%
43. Bronchoalveolar Lavage 20%
44. Retrospective Studies 18%
45. Vancomycin-Resistant Enterococci 18%
46. Smoke 17%
47. Tobacco Products 17%
48. Heart 17%
49. Human Influenza 17%
50. Thorax 17%